EE479 Cost-Effectiveness of Olaparib Compared to Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in United States

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.727
https://www.valueinhealthjournal.com/article/S1098-3015(22)00928-7/fulltext
Title : EE479 Cost-Effectiveness of Olaparib Compared to Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00928-7&doi=10.1016/j.jval.2022.04.727
First page :
Section Title :
Open access? : No
Section Order : 10654
Categories :
Tags :
Regions :
ViH Article Tags :